Teva begins plant expansion in Hungary
This article was originally published in Scrip
Teva Pharmaceutical Industriesis to expand its production facility in Debrecen, eastern Hungary, increasing its capacity by 20 billion tablets a year and creating more than 400 new jobs. The project is planned to be completed by 2011. Teva also wants to complete building its R&D centre in Debrecen by the end of next year. The company has invested $630 million in the country since 1995, and its sales in Hungary were Ft175 billion ($1.1 billion) last year.
You may also be interested in...
Poland's president, Bronislaw Komorowski, has signed a reimbursement bill into the law which will come into force on 1 January.
In the past two years, most multinational pharmaceutical companies announced plans to create production facilities in Russia. They had been ignoring such an opportunity for years, and there were reasons for that. They included risks to investments, administrative barriers, unclear regulations assuming various interpretations and corruption.
Russia's president Dmitriy Medvedev has requested that his government start talks with the US and the EU on the mutual recognition of clinical trial results (including paediatric trials) and prepare proposals for corresponding amendments of existing regulations.